Data on SAR-bisPSMA to be presented at EANM
Filed with ASX · · 7 pages · English
Summary by 6ix AI
Clarity Pharmaceuticals Ltd. has announced that data on SAR-bisPSMA will be presented at the European Association of Nuclear Medicine Annual Congress in Vienna, Austria, highlighting its potential in prostate cancer treatment. This announcement underscores the promising prospects of Clarity's products in changing the diagnostic and treatment landscape for prostate cancer.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Clarity Pharmaceuticals Ltd. on 6ix
Story so far
- Clarity signs a Commercial Manufacturing Agreement for Cu-64 SAR-bisPSMA with Nucleus RadioPharma
- Co-PSMA: Cu-64 SAR-bisPSMA more than doubled prostate cancer lesion and patient detection vs. Ga-68 PSMA-11 in head-to-head trial
- Clarity enters a Commercial Manufacturing Agreement for Cu-64 SAR-bisPSMA with SpectronRx
Earlier from Clarity Pharmaceuticals
- Clarity receives $9.8 million R&D tax incentive refund
- Clarity signs a Commercial Manufacturing Agreement for Cu-64 SAR-bisPSMA with Nucleus RadioPharma
- Clarity signs a Commercial Manufacturing Agreement
- Co-PSMA data published in the European Urology journal
- Clarity signs a large-scale Manufacturing Supply Agreement for copper-64 with Theragenics
Later from Clarity Pharmaceuticals
- SECuRE update
- Clarity Pharmaceuticals Announces SECuRE Trial Update on 8 GBq 67Cu-SAR-bisPSMA dose level with two additional complete responses
- Bioshares Biotech Summit Presentation
- Ph III CLARIFY trial target number of participants achieved
- Quarterly Activities/Appendix 4C Cash Flow Report
Follow Clarity Pharmaceuticals into a list and get an email when it puts out news.
Follow Clarity Pharmaceuticals